Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine Alkaloid Weight-Loss Claims Proposed Ban Lifted By FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA is withdrawing a proposed prohibition on claims that promote long-term use of ephedrine alkaloid-containing dietary supplements, such as claims for weight loss and bodybuilding.
Advertisement

Related Content

Weight Loss Products Aim To Be "Heavy" Hitters After NNFA Debut
Weight Loss Products Aim To Be "Heavy" Hitters After NNFA Debut
Ephedrine Alkaloid/Caffeine Combos Risk Unproven - Metabolife
Ephedrine Supplement Risks, Outcome Variables Subject Of USPHS Meeting
Dexatrim Natural Introduction Backed With $15 Mil. TV/Radio Campaign
Individual Susceptibility To Ephedrine Alkaloid AEs Cited By FDA Consultants
FDA and "street drug alternatives"
Ephedrine Alkaloid AERs Release Without FDA Analysis Urged By SBA
Ephedrine Alkaloids Dosing, Duration Limits Withdrawn Pending Public Input
Ephedrine Alkaloids Dosing, Duration Limits Withdrawn Pending Public Input

Topics

Advertisement
UsernamePublicRestriction

Register

PS091034

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel